PMID- 21808266 OWN - NLM STAT- MEDLINE DCOM- 20120126 LR - 20211020 IS - 1759-4782 (Electronic) IS - 1759-4774 (Print) IS - 1759-4774 (Linking) VI - 8 IP - 10 DP - 2011 Aug 2 TI - Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know. PG - 577-85 LID - 10.1038/nrclinonc.2011.116 [doi] AB - Cancer immunotherapy using the adoptive transfer of autologous tumor-infiltrating lymphocytes results in objective cancer regression in 49-72% of patients with metastatic melanoma. In a pilot trial combining cell transfer with a maximum lymphodepleting regimen, complete durable responses were seen in 40% of patients, with complete responses ongoing beyond 3 to 7 years. Current approaches to cell transfer therapy using autologous cells genetically engineered to express conventional or chimeric T-cell receptors have mediated cancer regression in patients with metastatic melanoma, synovial sarcoma, neuroblastoma and refractory lymphoma. Adoptive cell transfer immunotherapy is a rapidly developing new approach to the therapy of metastatic cancer in humans. This Review will emphasize the current available applications of cell transfer immunotherapy for patients with cancer. FAU - Rosenberg, Steven A AU - Rosenberg SA AD - Surgery Branch, National Cancer Institute, National Institutes of Health, CRC-Building 10, Room 3-3940, 10 Center Drive, Bethesda, MD 20892-1201, USA. sar@nih.gov LA - eng GR - Z01 BC010984-01/Intramural NIH HHS/United States PT - Journal Article PT - Review DEP - 20110802 PL - England TA - Nat Rev Clin Oncol JT - Nature reviews. Clinical oncology JID - 101500077 SB - IM MH - Adoptive Transfer MH - Humans MH - *Immunotherapy MH - Lymphocytes, Tumor-Infiltrating/*immunology MH - Neoplasm Metastasis MH - Neoplasms/immunology/*pathology/*therapy MH - T-Lymphocytes/cytology/*transplantation PMC - PMC6292196 MID - NIHMS999391 COIS- Competing interests The author, the journal Chief Editor L. Hutchinson and the CME questions author C. P. Vega declare no competing interests. EDAT- 2011/08/03 06:00 MHDA- 2012/01/27 06:00 PMCR- 2018/12/13 CRDT- 2011/08/03 06:00 PHST- 2011/08/03 06:00 [entrez] PHST- 2011/08/03 06:00 [pubmed] PHST- 2012/01/27 06:00 [medline] PHST- 2018/12/13 00:00 [pmc-release] AID - nrclinonc.2011.116 [pii] AID - 10.1038/nrclinonc.2011.116 [doi] PST - epublish SO - Nat Rev Clin Oncol. 2011 Aug 2;8(10):577-85. doi: 10.1038/nrclinonc.2011.116.